{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BIBW+2992+%28Afatinib%29", "query": { "intervention": "BIBW 2992 (Afatinib)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 66, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BIBW+2992+%28Afatinib%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-05T05:34:28.930Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04185883", "title": "Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Kirsten Rat Sarcoma (KRAS) pG12C Mutation" ], "interventions": [ { "name": "Sotorasib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "RMC-4630", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "Carboplatin, pemetrexed, docetaxel, paclitaxel", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "MVASI® (bevacizumab-awwb)", "type": "DRUG" }, { "name": "TNO155", "type": "DRUG" }, { "name": "IV Chemotherapy (Regimen 1)", "type": "DRUG" }, { "name": "IV Chemotherapy (Regimen 2)", "type": "DRUG" }, { "name": "BI 1701963", "type": "DRUG" }, { "name": "AMG 404", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 610, "start_date": "2019-12-17", "completion_date": "2027-12-05", "has_results": false, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-10-05T05:34:28.930Z", "location_count": 55, "location_summary": "Tucson, Arizona • Duarte, California • La Jolla, California + 42 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04185883" }, { "nct_id": "NCT02122172", "title": "Afatinib in Advanced Refractory Urothelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Distal Urethral Cancer", "Proximal Urethral Cancer", "Recurrent Bladder Cancer", "Recurrent Urethral Cancer", "Stage III Bladder Cancer", "Stage III Urethral Cancer", "Stage IV Bladder Cancer", "Stage IV Urethral Cancer", "Ureter Cancer" ], "interventions": [ { "name": "afatinib dimaleate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2017-09-13", "completion_date": "2024-04-04", "has_results": true, "last_update_posted_date": "2025-04-25", "last_synced_at": "2026-10-05T05:34:28.930Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Decatur, Illinois + 3 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02122172" }, { "nct_id": "NCT00514943", "title": "BIBW 2992 (Afatinib) in Head & Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Neoplasms", "Carcinoma, Squamous Cell" ], "interventions": [ { "name": "BIBW 2992", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2007-08", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2016-07-26", "last_synced_at": "2026-10-05T05:34:28.930Z", "location_count": 18, "location_summary": "Stanford, California • Chicago, Illinois • Harvey, Illinois + 14 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00514943" }, { "nct_id": "NCT02372006", "title": "Trial of Afatinib in Pediatric Tumours", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroectodermal Tumors", "Rhabdomyosarcoma" ], "interventions": [ { "name": "afatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 56, "start_date": "2015-04-29", "completion_date": "2020-08-05", "has_results": true, "last_update_posted_date": "2021-03-04", "last_synced_at": "2026-10-05T05:34:28.930Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Houston, Texas • Madison, Wisconsin", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02372006" }, { "nct_id": "NCT05070403", "title": "Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma" ], "interventions": [ { "name": "Afatinib 40 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2021-10-01", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-05T05:34:28.930Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05070403" }, { "nct_id": "NCT04497584", "title": "Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Squamous Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Afatinib + Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2021-08-04", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-10-05T05:34:28.930Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04497584" }, { "nct_id": "NCT03157089", "title": "Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Afatinib", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2017-11-02", "completion_date": "2020-01-13", "has_results": true, "last_update_posted_date": "2021-02-23", "last_synced_at": "2026-10-05T05:34:28.930Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03157089" }, { "nct_id": "NCT01649284", "title": "Afatinib Expanded Access Program", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "afatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2012-07", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2016-11-30", "last_synced_at": "2026-10-05T05:34:28.930Z", "location_count": 66, "location_summary": "Mobile, Alabama • Goodyear, Arizona • Hot Springs, Arkansas + 59 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01649284" }, { "nct_id": "NCT01824823", "title": "Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "afatinib", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2014-06-30", "completion_date": "2020-12", "has_results": true, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-10-05T05:34:28.930Z", "location_count": 272, "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • Fort Collins, Colorado + 186 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01824823" }, { "nct_id": "NCT06302621", "title": "Pemigatinib + Afatinib in Advanced Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Unresectable Solid Tumor", "Metastatic Solid Tumor", "Cholangiocarcinoma" ], "interventions": [ { "name": "Afatinib", "type": "DRUG" }, { "name": "Pemigatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2024-04-17", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-05T05:34:28.930Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06302621" } ] }